학술논문
Azacitidine 치료 후 폐 손상이 발생한 골수형성이상증후군
Azacitidine-Induced Lung Injury in a Patient with Myelodysplastic Syndrome
Azacitidine-Induced Lung Injury in a Patient with Myelodysplastic Syndrome
Document Type
Article
Author
김호철 / Ho Cheol Kim; 김상형 / Sang Hyung Kim; 안지환 / Jee Hwan Ahn; 권혜미 / Hye Mi Kwon; 최종한 / Jong Han Choi; 김태형 / Tae Hyung Kim; 이제환 / Je Hwan Lee
Source
대한내과학회지 (Korean J Med) / The Korean Journal of Medicine (Korean J Med). Oct 01, 2014 87(4):496
Subject
Language
Korean
ISSN
1738-9364
Abstract
In randomized phase 3 clinical trials azacitidine has been shown to prolong survival in patients with higher-risk myelodysplastic syndrome (MDS). Therefore, azacitidine therapy should be considered for treating MDS patients with higher-risk disease. A 78- year-old male was administered the first cycle of azacitidine treatment for higher-risk MDS. On day three of chemotherapy he complained of fever and dyspnea, and radiographic findings revealed bilateral perihilar-peribronchial infiltration and a small amount of pleural effusion. Considering the possibility of pneumonia, intravenous broad-spectrum antibiotics were administered and azacitidine therapy was discontinued. Upon improvement of the patient’s subjective symptoms and radiographic abnormalities, azacitidine therapy was resumed. However, fever and dyspnea developed again upon recommencement of azacitidine therapy. A diagnosis was made of azacitidine-induced lung injury and corticosteroid treatment was administered. Although lung injury is a rare complication induced by azacitidine, physicians should be aware of this life-threatening side effect. (Korean J Med 2014;87:496-500)